Brain Hemorrhages . Pituitary apoplexy following adenoviral vector-based COVID-19 vaccination

[tetano]

Brain Hemorrhages


. 2022 Apr 19.
doi: 10.1016/j.hest.2022.04.002. Online ahead of print.
Pituitary apoplexy following adenoviral vector-based COVID-19 vaccination


Luca Roncati ¹ , Antonio Manenti ¹



Affiliations

• PMID: 35464129
• PMCID: PMC9017089
• DOI: 10.1016/j.hest.2022.04.002

Abstract

Pituitary apoplexy (PA) may complicate the course of coronavirus disease 2019 (COVID-19), posing a potential threat to life. Among vaccines designed to prevent COVID-19, there are those adenoviral vector-based, such as Vaxzevria® (formerly COVID-19 Vaccine AstraZeneca). The product insert states that it can cause very rare coagulation disorders, in particular thrombosis with thrombocytopenia syndrome in some cases accompanied by bleeding, cerebrovascular venous or sinus thrombosis, and thrombocytopenia, including immune thrombocytopenia, also associated with bleeding. Here, we report the onset of PA after Vaxzevria® in a 28-year-old healthy Caucasian female, who experienced long-lasting tension-type headache, hyperprolactinemia and menstrual changes, without thrombocytopenia or thrombosis.

Keywords: COVID-19 Vaccine AstraZeneca; COVID-19, Coronavirus disease 2019; Coronavirus disease 2019 (COVID-19); MRI, Magnetic resonance imaging; Magnetic resonance imaging (MRI); Menstrual changes; PA, Pituitary apoplexy; Pituitary apoplexy; VITT, Vaccine-induced immune thrombotic thrombocytopenia; Vaxzevria®.